Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kodiak Sciences Inc. (KOD)
USD41.26
-2.00 (-4.62%)
US NASDAQ Healthcare Biotechnology
Address
1200 Page Mill Road 94304
Palo Alto, CA, US
Palo Alto, CA, US
CEO
Victor Perlroth
Website
kodiak.com
IPO
2018-10-04
CIK 1468748 ISIN US50015M1099
Description
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD41.26
-2.00 (-4.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
773.6K
Beta
2.20
Float Shares
48.99M
Free Float %
92.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.83% | -12.57% | -7.56% | +81.14% | +96.79% | +42.53% | +864.89% | +751.50% | +150.94% | +1,863.05% | +1,863.05% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
41.26
Low
56.00
+35.7%
Consensus
63.75
+54.5%
Median
59.50
+44.2%
High
80.00
+93.9%
DCF (Unlevered)
2.62
-93.6%
DCF (Levered)
2.83
-93.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 3 |
64.67
+56.7%
|
| Last Year | 6 |
49.83
+20.8%
|
| All Time | 18 |
32.67
-20.8%
|
Quality scores
Altman Z-Score
-2.87
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-29.0% Q1'26: +13.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-3,497.8% Q1'26: +16,639.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.2% ★ Q1'26: +17.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.25× Q1'26: -0.26× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 16.67M (-100.0%)
|
—
est: 17.86M (-100.0%)
|
—
est: 62.02M (-100.0%)
|
—
est: 602.3K (-100.0%)
|
11.32M
8.41M – 14.23M
+1,779.6% YoY
|
57.25M
46.99M – 72.84M
+405.8% YoY
|
236.30M
236.30M – 236.30M
+312.7% YoY
|
497.93M
370.05M – 625.88M
+110.7% YoY
|
870.81M
647.16M – 1.09B
+74.9% YoY
|
| EBITDA |
-46.45M
|
-128.86M
|
-149.50M
|
-234.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-47.36M
|
-133.07M
|
-176.21M
|
-234.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-47.37M
est: -62.57M (+24.3%)
|
-133.10M
est: -123.79M (-7.5%)
|
-176.21M
est: -183.47M (+4.0%)
|
-229.97M
est: -229.97M (+0.0%)
|
-239.55M
-247.56M – -137.41M
-4.2% YoY
|
-167.98M
-182.42M – -153.54M
+29.9% YoY
|
-46.13M
-81.00M – -11.26M
+72.5% YoY
|
56.67M
37.75M – 75.60M
+222.8% YoY
|
209.11M
139.29M – 278.96M
+269.0% YoY
|
| SGA |
10.77M
|
24.41M
|
34.05M
|
52.02M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.23
est: -1.19 (-3.4%)
|
-2.91
est: -2.35 (-23.6%)
|
-3.35
est: -3.39 (+1.3%)
|
-4.32
est: -4.27 (-1.2%)
|
-3.83
-4.65 – -2.58
+10.2% YoY
|
-3.21
-3.43 – -2.89
+16.2% YoY
|
-0.92
-1.52 – -0.21
+71.3% YoY
|
1.07
0.71 – 1.42
+215.4% YoY
|
3.93
2.62 – 5.24
+269.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
61
Total invested
165.57M
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Baker Bros. Advisors (GP) LLC | 9.30M | 24.40% | 9.30M | — | 9.30M | — | HC, OO | Delaware | 2018-10-12 | ↗ |
| 2 | Baker Bros. Advisors LP | 9.30M | 24.40% | 9.30M | — | 9.30M | — | IA, PN | Delaware | 2018-10-12 | ↗ |
| 3 | Felix J. Baker | 9.30M | 24.40% | 9.30M | — | 9.30M | — | HC, IN | United States | 2018-10-12 | ↗ |
| 4 | Julian C. Baker | 9.30M | 24.40% | 9.30M | — | 9.30M | — | HC, IN | United States | 2018-10-12 | ↗ |
| 5 | D. Victor Perlroth, M.D. | 6.26M | 11.60% | 6.26M | — | 5.73M | — | IN | — | 2022-02-14 | ↗ |
| 6 | (1) BlackRock, Inc. | 4.29M | 8.20% | 4.03M | — | 4.29M | — | HC | Delaware | 2023-02-03 | ↗ |
| 7 | Wellington Management Company LLP | 4.11M | 8.11% | — | 3.89M | — | — | IA | Massachusetts | 2021-02-04 | ↗ |
| 8 | 10 | 3.66M | 8.50% | — | 3.66M | — | 3.66M | IN | Delaware | 2020-02-14 | ↗ |
| 9 | 8.5% | 3.66M | 8.50% | — | 3.66M | — | 3.66M | CO | Delaware | 2020-02-14 | ↗ |
| 10 | Joseph Edelman | 3.17M | 8.70% | — | 3.17M | — | 3.17M | IN | America | 2018-10-19 | ↗ |
| 11 | Perceptive Advisors LLC | 3.17M | 8.70% | — | 3.17M | — | 3.17M | IA | Delaware | 2018-10-19 | ↗ |
| 12 | Perceptive Life Sciences Master Fund, Ltd. | 3.17M | 8.70% | — | 3.17M | — | 3.17M | CO | Islands | 2018-10-19 | ↗ |
| 13 | The Vanguard Group - 23-1945930 | 2.97M | 5.74% | — | 63.0K | 2.88M | 91.8K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 14 | 52-0556948 | 2.69M | 5.10% | 791.6K | — | 2.69M | — | IA | Maryland | 2022-03-10 | ↗ |
| 15 | Wellington Group Holdings LLP | 1.65M | 3.20% | — | 1.37M | — | — | HC | Massachusetts | 2022-03-10 | ↗ |
| 16 | Wellington Investment Advisors Holdings LLP | 1.65M | 3.20% | — | 1.37M | — | — | HC | Massachusetts | 2022-03-10 | ↗ |
| 17 | Wellington Management Group LLP | 1.65M | 3.20% | — | 1.37M | — | — | HC | Massachusetts | 2022-03-10 | ↗ |
| 18 | Dustin A. Moskovitz | 1.38M | 2.70% | 1.38M | — | 1.38M | — | IN | — | 2021-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
61
-106 vs prev Q
New positions
20
Closed positions
118
Increased
36
Reduced
14
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 19.92M +2.6M (+15.1%) | 556.94M +273.6M (+96.5%) | 37.68% +4.885 pp | 3.26% +1.213 pp | USD10.44 +167.8% | 29 qtrs — |
| 2 | BLACKROCK, INC. | 3.95M +1.0M (+33.9%) | 110.57M +62.2M (+128.8%) | 7.48% +1.888 pp | 0.00% +0.001 pp | USD9.03 +209.6% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 2.31M +363.1K (+18.6%) | 64.68M +32.8M (+102.6%) | 4.38% +0.681 pp | 0.00% +0.001 pp | USD14.25 +96.2% | 29 qtrs — |
| 4 | POINT72 ASSET MANAGEMENT, L.P. | 2.17M -670.2K (-23.6%) | 60.59M +14.1M (+30.5%) | 4.10% -1.276 pp | 0.07% -0.010 pp | USD14.76 +89.4% | 5 qtrs — |
| 5 | BRAIDWELL LP | 2.07M +2.1M (+100.0%) | 57.96M +58.0M (+100.0%) | 3.92% +3.921 pp | 1.85% +1.853 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 6 | STATE STREET CORP | 1.73M +899.6K (+108.1%) | 48.43M +34.8M (+255.4%) | 3.28% +1.699 pp | 0.00% +0.001 pp | USD18.73 +49.3% | 29 qtrs — |
| 7 | RTW INVESTMENTS, LP | 1.49M +1.5M (+100.0%) | 41.60M +41.6M (+100.0%) | 2.81% +2.815 pp | 0.42% +0.417 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 8 | TCG CROSSOVER MANAGEMENT, LLC | 1.45M +300.0K (+26.2%) | 40.42M +21.7M (+115.5%) | 2.73% +0.564 pp | 1.34% +0.415 pp | USD9.45 +195.9% | 9 qtrs — |
| 9 | GOLDMAN SACHS GROUP INC | 1.30M +976.3K (+298.8%) | 36.43M +31.1M (+581.1%) | 2.47% +1.846 pp | 0.00% +0.004 pp | USD24.56 +13.8% | 29 qtrs — |
| 10 | ICONIQ CAPITAL, LLC | 1.27M +— (+0.0%) | 35.41M +14.7M (+70.8%) | 2.40% -0.004 pp | 0.53% +0.277 pp | USD2.87 +874.2% | 26 qtrs — |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.17M +668.0K (+133.0%) | 32.72M +24.5M (+297.9%) | 2.21% +1.262 pp | 0.00% +0.003 pp | USD22.76 +22.8% | 6 qtrs — |
| 12 | BOXER CAPITAL MANAGEMENT, LLC | 1.14M +386.0K (+51.5%) | 31.76M +19.5M (+158.7%) | 2.15% +0.728 pp | 6.95% +3.039 pp | USD15.91 +75.7% | 5 qtrs — |
| 13 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.02M +23.1K (+2.3%) | 28.61M +12.2M (+74.7%) | 1.94% +0.041 pp | 3.97% +1.766 pp | USD12.61 +121.7% | 10 qtrs — |
| 14 | JANUS HENDERSON GROUP PLC | 1.00M +1.0M (+100.0%) | 27.95M +28.0M (+100.0%) | 1.89% +1.892 pp | 0.01% +0.013 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 897.7K +96.3K (+12.0%) | 25.11M +12.0M (+91.3%) | 1.70% +0.180 pp | 0.00% +0.001 pp | USD11.51 +142.9% | 29 qtrs — |
| 16 | PERCEPTIVE ADVISORS LLC | 848.9K +214.3K (+33.8%) | 23.74M +13.3M (+128.5%) | 1.61% +0.404 pp | 0.42% +0.123 pp | USD19.30 +44.9% | 2 qtrs — |
| 17 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 836.5K +836.5K (+100.0%) | 23.39M +23.4M (+100.0%) | 1.58% +1.583 pp | 0.04% +0.035 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 785.0K -550.0K (-41.2%) | 21.95M +94.7K (+0.4%) | 1.49% -1.044 pp | 0.03% -0.001 pp | USD7.09 +294.4% | 5 qtrs — |
| 19 | IKARIAN CAPITAL, LLC | 719.8K +305.9K (+73.9%) | 20.13M +13.4M (+197.1%) | 1.36% +0.578 pp | 1.57% +0.887 pp | USD14.21 +96.8% | 12 qtrs — |
| 20 | ACADIAN ASSET MANAGEMENT LLC | 709.8K -260.1K (-26.8%) | 19.84M +4.0M (+25.0%) | 1.34% -0.495 pp | 0.03% +0.005 pp | USD3.17 +782.0% | 16 qtrs — |
| 21 | MORGAN STANLEY | 699.8K +52.2K (+8.1%) | 19.57M +9.0M (+84.6%) | 1.32% +0.097 pp | 0.00% +0.001 pp | USD13.55 +106.3% | 29 qtrs — |
| 22 | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 691.8K +— (+0.0%) | 19.34M +8.0M (+70.8%) | 1.31% -0.002 pp | 3.90% +2.567 pp | USD1.42 +1,869.0% | 29 qtrs — |
| 23 | INVESCO LTD. | 555.1K +454.9K (+454.1%) | 15.52M +13.9M (+846.4%) | 1.05% +0.860 pp | 0.00% +0.002 pp | USD24.88 +12.4% | 26 qtrs — |
| 24 | BOONE CAPITAL MANAGEMENT LLC | 503.8K -212.0K (-29.6%) | 14.09M +2.4M (+20.2%) | 0.95% -0.403 pp | 4.42% +0.579 pp | USD16.37 +70.8% | 2 qtrs — |
| 25 | WELLINGTON MANAGEMENT GROUP LLP | 473.8K +356.7K (+304.7%) | 13.25M +11.3M (+591.3%) | 0.90% +0.675 pp | 0.00% +0.002 pp | USD22.63 +23.6% | 3 qtrs — |
| 26 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 409.1K +409.1K (+100.0%) | 11.44M +11.4M (+100.0%) | 0.77% +0.774 pp | 0.01% +0.007 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 27 | RENAISSANCE TECHNOLOGIES LLC | 359.8K -101.5K (-22.0%) | 10.06M +2.5M (+33.2%) | 0.68% -0.193 pp | 0.02% +0.006 pp | USD3.78 +639.7% | 15 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 340.7K +61.2K (+21.9%) | 9.52M +4.9M (+108.2%) | 0.64% +0.115 pp | 0.00% +0.001 pp | USD13.20 +111.8% | 29 qtrs — |
| 29 | NORTHERN TRUST CORP | 333.7K -4.2K (-1.3%) | 9.33M +3.8M (+68.7%) | 0.63% -0.009 pp | 0.00% +0.001 pp | USD5.93 +371.5% | 29 qtrs — |
| 30 | DIMENSIONAL FUND ADVISORS LP | 327.5K -190.5K (-36.8%) | 9.16M +678.6K (+8.0%) | 0.62% -0.362 pp | 0.00% +0.000 pp | USD6.67 +319.2% | 21 qtrs — |
| 31 | D. E. SHAW & CO., INC. | 320.6K -137.2K (-30.0%) | 8.97M +1.5M (+19.6%) | 0.61% -0.261 pp | 0.00% +0.001 pp | USD6.92 +304.0% | 25 qtrs — |
| 32 | — | 291.7K +291.7K (+100.0%) | 8.16M +8.2M (+100.0%) | 0.55% +0.552 pp | 3.46% +3.456 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 33 | CITADEL ADVISORS LLC | 290.5K +245.0K (+539.0%) | 8.12M +7.4M (+991.5%) | 0.55% +0.463 pp | 0.00% +0.001 pp | USD26.15 +6.9% | 2 qtrs — |
| 34 | JAIN GLOBAL LLC | 284.9K +284.9K (+100.0%) | 7.97M +8.0M (+100.0%) | 0.54% +0.539 pp | 0.04% +0.039 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 35 | BALYASNY ASSET MANAGEMENT L.P. | 263.3K +247.9K (+1,607.5%) | 7.36M +7.1M (+2,816.4%) | 0.50% +0.469 pp | 0.01% +0.009 pp | USD27.28 +2.5% | 2 qtrs — |
| 36 | FEDERATED HERMES, INC. | 244.2K +— (+0.0%) | 6.83M +2.8M (+70.8%) | 0.46% -0.001 pp | 0.01% +0.004 pp | USD3.41 +719.9% | 4 qtrs — |
| 37 | ATOM INVESTORS LP | 207.5K +207.5K (+100.0%) | 5.80M +5.8M (+100.0%) | 0.39% +0.393 pp | 0.46% +0.461 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 38 | FMR LLC | 199.2K -63.9K (-24.3%) | 5.57M +1.3M (+29.3%) | 0.38% -0.122 pp | 0.00% +0.000 pp | USD4.75 +488.6% | 25 qtrs — |
| 39 | BANK OF AMERICA CORP /DE/ | 196.7K -112.4K (-36.4%) | 5.50M +439.9K (+8.7%) | 0.37% -0.214 pp | 0.00% +0.000 pp | USD14.60 +91.5% | 29 qtrs — |
| 40 | TREXQUANT INVESTMENT LP | 190.5K +143.3K (+303.1%) | 5.33M +4.6M (+588.6%) | 0.36% +0.271 pp | 0.05% +0.040 pp | USD25.09 +11.4% | 2 qtrs — |
| 41 | PANAGORA ASSET MANAGEMENT INC | 180.7K +25.8K (+16.7%) | 5.05M +2.5M (+99.3%) | 0.34% +0.048 pp | 0.02% +0.008 pp | USD8.38 +233.7% | 7 qtrs — |
| 42 | SPHERA FUNDS MANAGEMENT LTD. | 175.5K +175.5K (+100.0%) | 4.91M +4.9M (+100.0%) | 0.33% +0.332 pp | 0.95% +0.949 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 43 | BOOTHBAY FUND MANAGEMENT, LLC | 173.2K +56.8K (+48.8%) | 4.84M +2.9M (+154.1%) | 0.33% +0.107 pp | 0.07% +0.045 pp | USD12.01 +132.8% | 12 qtrs — |
| 44 | UBS GROUP AG | 168.6K +111.9K (+197.2%) | 4.71M +3.8M (+407.7%) | 0.32% +0.211 pp | 0.00% +0.001 pp | USD21.69 +28.9% | 14 qtrs — |
| 45 | BRUCE & CO., INC. | 165.0K -114.3K (-40.9%) | 4.61M +41.1K (+0.9%) | 0.31% -0.217 pp | 1.43% +0.015 pp | USD6.20 +351.0% | 12 qtrs — |
| 46 | TD ASSET MANAGEMENT INC | 133.9K +73.3K (+121.0%) | 3.74M +2.8M (+277.4%) | 0.25% +0.139 pp | 0.00% +0.002 pp | USD22.72 +23.1% | 2 qtrs — |
| 47 | JACOBS LEVY EQUITY MANAGEMENT, INC | 127.2K -38.0K (-23.0%) | 3.56M +852.7K (+31.5%) | 0.24% -0.072 pp | 0.01% +0.003 pp | USD3.42 +717.5% | 14 qtrs — |
| 48 | BARCLAYS PLC | 124.3K +44.7K (+56.1%) | 3.48M +3.3M (+1,572.1%) | 0.24% +0.084 pp | 0.00% +0.001 pp | USD12.60 +121.9% | 28 qtrs — |
| 49 | RIA ADVISORY GROUP LLC | 113.5K -52.1K (-31.5%) | 3.17M +462.9K (+17.1%) | 0.21% -0.099 pp | 0.76% +0.068 pp | USD4.91 +469.5% | 6 qtrs — |
| 50 | TWO SIGMA ADVISERS, LP | 103.1K -106.3K (-50.8%) | 2.88M -545.2K (-15.9%) | 0.20% -0.202 pp | 0.01% -0.001 pp | USD6.88 +306.4% | 24 qtrs — |
| 51 | BANK OF NEW YORK MELLON CORP | 102.7K -1.7K (-1.7%) | 2.87M +1.2M (+68.0%) | 0.19% -0.004 pp | 0.00% +0.000 pp | USD11.06 +152.8% | 29 qtrs — |
| 52 | WELLS FARGO & COMPANY/MN | 92.1K +65.7K (+248.8%) | 2.58M +2.1M (+495.7%) | 0.17% +0.124 pp | 0.00% +0.000 pp | USD21.22 +31.8% | 29 qtrs — |
| 53 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 91.5K +50.2K (+121.8%) | 2.56M +1.9M (+278.7%) | 0.17% +0.095 pp | 0.00% +0.002 pp | USD22.73 +23.0% | 5 qtrs — |
| 54 | ADVISOR GROUP HOLDINGS, INC. | 83.4K +73.3K (+726.0%) | 2.33M +2.2M (+1,453.6%) | 0.16% +0.139 pp | 0.00% +0.003 pp | USD25.35 +10.3% | 24 qtrs — |
| 55 | PRUDENTIAL FINANCIAL INC | 78.3K +16.0K (+25.6%) | 2.19M +1.2M (+114.6%) | 0.15% +0.030 pp | 0.00% +0.001 pp | USD18.73 +49.3% | 2 qtrs — |
| 56 | NUVEEN, LLC | 73.0K -48.4K (-39.8%) | 2.04M +54.8K (+2.8%) | 0.14% -0.092 pp | 0.00% +0.000 pp | USD2.81 +895.0% | 4 qtrs — |
| 57 | NEW YORK STATE COMMON RETIREMENT FUND | 67.3K +65.6K (+4,023.9%) | 1.88M +1.9M (+6,943.7%) | 0.13% +0.124 pp | 0.00% +0.003 pp | USD27.71 +0.9% | 28 qtrs — |
| 58 | HARVEST INVESTMENT SERVICES, LLC | 62.0K +62.0K (+100.0%) | 1.73M +1.7M (+100.0%) | 0.12% +0.117 pp | 0.33% +0.327 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 59 | MILLENNIUM MANAGEMENT LLC | 60.6K -94.6K (-61.0%) | 1.69M -846.6K (-33.3%) | 0.11% -0.180 pp | 0.00% 0.000 pp | USD16.37 +70.8% | 27 qtrs — |
| 60 | SOLEUS CAPITAL MANAGEMENT, L.P. | 60.0K +40.4K (+205.4%) | 1.68M +1.4M (+421.7%) | 0.11% +0.076 pp | 0.06% +0.046 pp | USD24.17 +15.7% | 2 qtrs — |
| 61 | RAFFERTY ASSET MANAGEMENT, LLC | 59.5K +59.5K (+100.0%) | 1.66M +1.7M (+100.0%) | 0.11% +0.113 pp | 0.01% +0.006 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 62 | AQR CAPITAL MANAGEMENT LLC | 57.7K +16.5K (+40.1%) | 1.61M +939.1K (+139.3%) | 0.11% +0.031 pp | 0.00% +0.000 pp | USD10.01 +179.3% | 16 qtrs — |
| 63 | TWO SIGMA INVESTMENTS, LP | 51.7K -86.6K (-62.6%) | 1.44M -818.6K (-36.2%) | 0.10% -0.164 pp | 0.00% -0.001 pp | USD11.46 +144.0% | 26 qtrs — |
| 64 | NORGES BANK | 50.0K +50.0K (+100.0%) | 1.40M +1.4M (+100.0%) | 0.09% +0.095 pp | 0.00% +0.000 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 65 | VICTORY CAPITAL MANAGEMENT INC | 44.0K +44.0K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.08% +0.083 pp | 0.00% +0.001 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 66 | CAMPBELL & CO INVESTMENT ADVISER LLC | 43.4K +13.6K (+45.5%) | 1.21M +724.7K (+148.5%) | 0.08% +0.026 pp | 0.06% +0.021 pp | USD20.00 +39.8% | 2 qtrs — |
| 67 | RHUMBLINE ADVISERS | 43.2K -5.2K (-10.8%) | 1.21M +415.8K (+52.4%) | 0.08% -0.010 pp | 0.00% +0.000 pp | USD8.18 +241.8% | 27 qtrs — |
| 68 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 43.2K -29.0K (-40.2%) | 1.21M +26.0K (+2.2%) | 0.08% -0.055 pp | 0.03% +0.000 pp | USD2.98 +838.3% | 9 qtrs — |
| 69 | POLEN CAPITAL MANAGEMENT LLC | 41.3K +19.8K (+91.7%) | 1.16M +802.8K (+227.4%) | 0.08% +0.037 pp | 0.00% +0.004 pp | USD21.91 +27.6% | 2 qtrs — |
| 70 | Y-INTERCEPT (HONG KONG) LTD | 38.0K +38.0K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.07% +0.072 pp | 0.02% +0.024 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 71 | STATE OF WISCONSIN INVESTMENT BOARD | 36.8K -5.9K (-13.9%) | 1.03M +329.4K (+47.1%) | 0.07% -0.011 pp | 0.00% +0.001 pp | USD5.53 +405.6% | 5 qtrs — |
| 72 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 36.7K -134.7K (-78.6%) | 1.03M -1.8M (-63.4%) | 0.07% -0.255 pp | 0.00% 0.000 pp | USD13.12 +113.1% | 26 qtrs — |
| 73 | DEUTSCHE BANK AG\ | 35.3K +4.6K (+14.9%) | 987.5K +484.5K (+96.3%) | 0.07% +0.009 pp | 0.00% +0.000 pp | USD7.30 +283.0% | 29 qtrs — |
| 74 | ALLIANCEBERNSTEIN L.P. | 35.2K -19.9K (-36.1%) | 983.6K +82.3K (+9.1%) | 0.07% -0.038 pp | 0.00% +0.000 pp | USD15.97 +75.1% | 27 qtrs — |
| 75 | RUSSELL INVESTMENTS GROUP, LTD. | 31.7K -4.2K (-11.8%) | 886.8K +298.2K (+50.7%) | 0.06% -0.008 pp | 0.00% +0.000 pp | USD8.69 +221.7% | 26 qtrs — |
| 76 | TUDOR INVESTMENT CORP ET AL | 30.8K -59.3K (-65.8%) | 861.2K -613.8K (-41.6%) | 0.06% -0.112 pp | 0.00% -0.001 pp | USD16.37 +70.8% | 2 qtrs — |
| 77 | DIADEMA PARTNERS LP | 29.6K +1.8K (+6.5%) | 827.6K +372.5K (+81.9%) | 0.06% +0.003 pp | 0.14% +0.026 pp | USD17.07 +63.8% | 2 qtrs — |
| 78 | FOX RUN MANAGEMENT, L.L.C. | 29.4K +17.0K (+136.1%) | 822.6K +618.6K (+303.3%) | 0.06% +0.032 pp | 0.13% +0.095 pp | USD23.05 +21.3% | 2 qtrs — |
| 79 | J. GOLDMAN & CO LP | 28.9K +28.9K (+100.0%) | 809.4K +809.4K (+100.0%) | 0.05% +0.055 pp | 0.02% +0.021 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 80 | JANE STREET GROUP, LLC | 25.1K +7.0K (+38.7%) | 701.8K +405.5K (+136.9%) | 0.05% +0.013 pp | 0.00% +0.000 pp | USD19.60 +42.7% | 2 qtrs — |
| 81 | ARIES WEALTH MANAGEMENT | 25.0K +— (+0.0%) | 699.0K +289.8K (+70.8%) | 0.05% 0.000 pp | 0.15% +0.058 pp | USD2.81 +895.0% | 4 qtrs — |
| 82 | SG AMERICAS SECURITIES, LLC | 24.1K +10.2K (+73.5%) | 675.0K +447.0K (+196.1%) | 0.05% +0.019 pp | 0.00% +0.000 pp | USD21.28 +31.4% | 2 qtrs — |
| 83 | PROFUND ADVISORS LLC | 22.1K +22.1K (+100.0%) | 617.7K +617.7K (+100.0%) | 0.04% +0.042 pp | 0.02% +0.019 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 84 | SEI INVESTMENTS CO | 20.7K +20.7K (+100.0%) | 577.8K +577.8K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.001 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 85 | AMERIPRISE FINANCIAL INC | 19.9K -29.0K (-59.3%) | 556.3K -243.4K (-30.4%) | 0.04% -0.055 pp | 0.00% 0.000 pp | USD3.88 +620.6% | 14 qtrs — |
| 86 | FRANKLIN RESOURCES INC | 19.5K +19.5K (+100.0%) | 546.0K +546.0K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 87 | METLIFE INVESTMENT MANAGEMENT, LLC | 19.4K +— (+0.0%) | 543.2K +225.2K (+70.8%) | 0.04% 0.000 pp | 0.00% +0.001 pp | USD16.37 +70.8% | 2 qtrs — |
| 88 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 18.7K +3.7K (+24.9%) | 521.9K +277.1K (+113.2%) | 0.04% +0.007 pp | 0.00% +0.000 pp | USD7.64 +266.0% | 7 qtrs — |
| 89 | LPL FINANCIAL LLC | 18.4K +18.4K (+100.0%) | 514.4K +514.4K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.000 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 90 | JPMORGAN CHASE & CO | 17.9K +4.7K (+35.7%) | 500.6K +284.6K (+131.8%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD13.50 +107.1% | 29 qtrs — |
| 91 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 17.2K +17.2K (+100.0%) | 481.1K +481.1K (+100.0%) | 0.03% +0.033 pp | 0.01% +0.005 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 92 | ARTIA GLOBAL PARTNERS LP | 17.0K +17.0K (+100.0%) | 475.9K +475.9K (+100.0%) | 0.03% +0.032 pp | 0.08% +0.076 pp | USD27.96 +0.0% | 1 qtrs NEW |
| 93 | CITIGROUP INC | 16.6K +8.0K (+93.8%) | 464.6K +324.3K (+231.0%) | 0.03% +0.015 pp | 0.00% +0.000 pp | USD15.19 +84.1% | 29 qtrs — |
| 94 | CERITY PARTNERS LLC | 16.4K +1.1K (+7.4%) | 459.8K +209.3K (+83.5%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD4.37 +539.8% | 8 qtrs — |
| 95 | HEADLANDS TECHNOLOGIES LLC | 16.3K -13.5K (-45.3%) | 455.1K -31.6K (-6.5%) | 0.03% -0.026 pp | 0.04% -0.001 pp | USD13.41 +108.5% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 90 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.75% | 429.7K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.57% | 206.2K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.57% | 61.94M | 0.35% |
| 4 | Vanguard Global Momentum Factor ETF VMO.TO | 0.22% | 804.1K | 0.38% |
| 5 | iShares Biotechnology ETF IBB | 0.18% | 17.28M | 0.44% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.18% | 133.3K | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.18% | 1.99M | 0.35% |
| 8 | T. Rowe Price Innovation Leaders ETF TNXT | 0.18% | 32.9K | 0.49% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.18% | 823.0K | 0.40% |
| 10 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.18% | 132.8K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
0.66
Neutral
Buys
2
Sells
6
Shares acquired
58.6K
Shares disposed
88.6K
Cash buys
—
Cash sales
4.00
Net activity
-30,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 28,614 | 1.04 | 29.8K | 211,930 | D | ↗ |
| 2026-04-02 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 30,000 | 1.04 | 31.2K | 213,316 | D | ↗ |
| 2026-03-25 | PERLROTH VICTOR | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 300,000 | 1.04 | 312.0K | 0 | D | ↗ |
| 2026-03-18 | PERLROTH VICTOR | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 25.00 | 4.38M | 175,000 | D | ↗ |
| 2025-12-31 | PERLROTH VICTOR | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-18 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 2,391,268 | 23.00 | 55.00M | 18,358,772 | I | ↗ |
| 2025-07-04 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 340,000 | 3.95 | 1.34M | 340,000 | D | ↗ |
| 2025-07-04 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 3.95 | 987.5K | 250,000 | D | ↗ |
| 2025-06-30 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.73 | 149.2K | 40,000 | D | ↗ |
| 2025-06-30 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.73 | 149.2K | 40,000 | D | ↗ |
| 2025-06-30 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.73 | 149.2K | 40,000 | D | ↗ |
| 2025-06-30 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.73 | 149.2K | 40,000 | D | ↗ |
| 2025-06-30 | Bancroft Charles A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.73 | 149.2K | 40,000 | D | ↗ |
| 2025-06-30 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non- Qualified Stock Options (right to buy) | 40,000 | 3.73 | 149.2K | 40,000 | I | ↗ |
| 2025-06-17 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 723 | 3.65 | 2.6K | 183,316 | D | ↗ |
| 2025-06-15 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 1,875 | 0.00 | — | 184,039 | D | ↗ |
| 2024-08-05 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 406,000 | 2.49 | 1.01M | 406,000 | — | ↗ |
| 2024-08-05 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 334,500 | 2.49 | 832.9K | 334,500 | — | ↗ |
| 2024-06-28 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.35 | 94.0K | 40,000 | — | ↗ |
| 2024-06-28 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.35 | 94.0K | 40,000 | — | ↗ |
| 2024-06-28 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.35 | 94.0K | 40,000 | — | ↗ |
| 2024-06-28 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.35 | 94.0K | 40,000 | — | ↗ |
| 2024-06-28 | Bancroft Charles A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.35 | 94.0K | 40,000 | — | ↗ |
| 2024-06-28 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non- Qualified Stock Options (right to buy) | 40,000 | 2.35 | 94.0K | 40,000 | — | ↗ |
| 2024-06-17 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 2,874 | 2.75 | 7.9K | 182,164 | — | ↗ |
| 2024-06-15 | BORGESON JOHN A. | Officer | M-Exempt | D | Restricted Stock Units | 3,619 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 1,558 | 2.92 | 4.5K | 179,544 | — | ↗ |
| 2024-06-11 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 3,025 | 0.00 | — | 181,102 | — | ↗ |
| 2023-06-30 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 6.90 | 276.0K | 40,000 | — | ↗ |
| 2023-06-30 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 6.90 | 276.0K | 40,000 | — | ↗ |
| 2023-06-30 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 6.90 | 276.0K | 40,000 | — | ↗ |
| 2023-06-30 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 6.90 | 276.0K | 40,000 | — | ↗ |
| 2023-06-30 | Bancroft Charles A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 6.90 | 276.0K | 40,000 | — | ↗ |
| 2023-06-30 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 40,000 | 6.90 | 276.0K | 40,000 | — | ↗ |
| 2023-06-24 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 335,000 | 7.24 | 2.43M | 335,000 | — | ↗ |
| 2023-06-24 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 207,500 | 7.24 | 1.50M | 207,500 | — | ↗ |
| 2023-06-24 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 207,500 | 7.24 | 1.50M | 207,500 | — | ↗ |
| 2023-06-16 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 2,258 | 9.23 | 20.8K | 61,924 | — | ↗ |
| 2023-06-16 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 2,749 | 9.23 | 25.4K | 178,077 | — | ↗ |
| 2023-06-15 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 5,494 | 0.00 | — | 64,182 | — | ↗ |
| 2023-06-15 | BORGESON JOHN A. | Officer | M-Exempt | D | Restricted Stock Units | 3,619 | 0.00 | — | 3,619 | — | ↗ |
| 2023-06-14 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 1,132 | 9.42 | 10.7K | 58,688 | — | ↗ |
| 2023-06-14 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 1,448 | 9.42 | 13.6K | 175,332 | — | ↗ |
| 2023-06-11 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 2,900 | 0.00 | — | 59,820 | — | ↗ |
| 2023-06-11 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 3,025 | 0.00 | — | 176,780 | — | ↗ |
| 2022-12-31 | PERLROTH VICTOR | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-06 | PERLROTH VICTOR | Officer | A-Award | A | Stock Option (Right to Buy) | 325,000 | 0.00 | — | 325,000 | — | ↗ |
| 2022-07-06 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 142,500 | 8.15 | 1.16M | 142,500 | — | ↗ |
| 2022-07-06 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 142,500 | 0.00 | — | 142,500 | — | ↗ |
| 2022-06-30 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-30 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-30 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-30 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-30 | Bancroft Charles A | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 7.64 | 191.0K | 25,000 | — | ↗ |
| 2022-06-30 | BAKER FELIX | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-30 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 25,000 | 7.64 | 191.0K | 25,000 | — | ↗ |
| 2022-06-15 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 5,494 | 0.00 | — | 60,407 | — | ↗ |
| 2022-06-15 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 2,798 | 7.02 | 19.6K | 173,755 | — | ↗ |
| 2022-06-11 | EHRLICH JASON | Officer | M-Exempt | D | Restricted Stock Units | 2,900 | 0.00 | — | 5,800 | — | ↗ |
| 2022-06-11 | BORGESON JOHN A. | Officer | M-Exempt | D | Restricted Stock Units | 3,025 | 0.00 | — | 6,050 | — | ↗ |
| 2022-06-06 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 170,549 | 7.78 | 1.33M | 15,967,504 | — | ↗ |
| 2022-06-03 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 9,224 | 7.95 | 73.4K | 1,310,933 | — | ↗ |
| 2022-06-02 | BAKER FELIX | Director | P-Purchase | A | Common Stock | 13,155 | 7.93 | 104.4K | 15,617,369 | — | ↗ |
| 2022-06-02 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,247 | 7.51 | 9.4K | 1,283,881 | — | ↗ |
| 2022-05-27 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 88,046 | 6.92 | 609.3K | 15,455,507 | — | ↗ |
| 2022-05-26 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 6,299 | 6.75 | 42.5K | 1,266,064 | — | ↗ |
| 2022-05-25 | BAKER FELIX | Director | P-Purchase | A | Common Stock | 116 | 6.76 | 783.58 | 1,266,180 | — | ↗ |
| 2022-05-25 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 4,984 | 6.60 | 32.9K | 1,256,333 | — | ↗ |
| 2022-05-18 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,115 | 5.95 | 6.6K | 1,222,483 | — | ↗ |
| 2022-05-17 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 90,674 | 5.99 | 542.9K | 14,942,601 | — | ↗ |
| 2022-05-16 | BAKER FELIX | Director | P-Purchase | A | Common Stock | 8,118 | 5.99 | 48.6K | 14,851,927 | — | ↗ |
| 2022-05-16 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,846 | 5.75 | 10.6K | 1,209,336 | — | ↗ |
| 2022-02-25 | PERLROTH VICTOR | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 340,000 | 8.99 | 3.06M | 2,168,038 | — | ↗ |
| 2022-02-24 | PERLROTH VICTOR | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,000,000 | 9.20 | 9.20M | 2,508,038 | — | ↗ |
| 2022-02-17 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 271,997 | 54.57 | 14.84M | 14,734,965 | — | ↗ |
| 2022-02-16 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 60,000 | 131.44 | 7.89M | 60,000 | — | ↗ |
| 2022-02-16 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 131.44 | 1.97M | 15,000 | — | ↗ |
| 2022-02-16 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 131.44 | 1.97M | 15,000 | — | ↗ |
| 2022-02-16 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 64,119 | 54.26 | 3.48M | 14,457,794 | — | ↗ |
| 2022-02-15 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 5,359 | 54.16 | 290.2K | 14,369,871 | — | ↗ |
| 2022-01-31 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 27,841 | 57.22 | 1.59M | 14,364,512 | — | ↗ |
| 2022-01-28 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,851 | 49.70 | 92.0K | 1,160,894 | — | ↗ |
| 2022-01-27 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 54,024 | 51.67 | 2.79M | 14,285,631 | — | ↗ |
| 2022-01-25 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 5,500 | 58.90 | 323.9K | 14,027,837 | — | ↗ |
| 2022-01-24 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 25,900 | 57.59 | 1.49M | 13,823,073 | — | ↗ |
| 2022-01-21 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 31,207 | 57.53 | 1.80M | 13,660,140 | — | ↗ |
| 2022-01-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 2,416 | 63.55 | 153.5K | 55,267 | — | ↗ |
| 2021-12-20 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 225,488 | — | ↗ |
| 2021-11-22 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 6,950 | 10.29 | 71.5K | 58,491 | — | ↗ |
| 2021-11-10 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 204 | 116.29 | 23.7K | 169,443 | — | ↗ |
| 2021-10-20 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 6,950 | 10.29 | 71.5K | 58,491 | — | ↗ |
| 2021-09-30 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 86,932 | 95.83 | 8.33M | 13,526,726 | — | ↗ |
| 2021-09-29 | BAKER BROS. ADVISORS LP | Director / 10% Owner | M-Exempt | A | Common Stock | 138,815 | 0.01 | 1.4K | 13,439,808 | — | ↗ |
| 2021-09-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 503 | 100.52 | 50.6K | 51,890 | — | ↗ |
| 2021-09-16 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,153 | 94.59 | 109.1K | 13,300,993 | — | ↗ |
| 2021-09-15 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 400 | 94.48 | 37.8K | 13,299,840 | — | ↗ |
| 2021-09-07 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 52,201 | 93.35 | 4.87M | 13,269,155 | — | ↗ |
| 2021-08-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 542 | 90.64 | 49.1K | 57,035 | — | ↗ |
| 2021-08-19 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 73,635 | 87.61 | 6.45M | 13,211,654 | — | ↗ |
| 2021-08-18 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 8,186 | 87.91 | 719.7K | 13,126,506 | — | ↗ |
| 2021-08-17 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 7,764 | 85.95 | 667.3K | 13,105,422 | — | ↗ |
| 2021-08-13 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 400 | 88.82 | 35.5K | 13,097,258 | — | ↗ |
| 2021-08-12 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 241,000 | 88.21 | 21.26M | 241,000 | — | ↗ |
| 2021-08-12 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 88.21 | 4.41M | 50,000 | — | ↗ |
| 2021-08-12 | BORGESON JOHN A. | Officer | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2021-08-12 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 6,086 | 88.01 | 535.6K | 13,058,994 | — | ↗ |
| 2021-08-11 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 600 | 85.72 | 51.4K | 12,998,808 | — | ↗ |
| 2021-07-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 2,234 | 85.76 | 191.6K | 57,949 | — | ↗ |
| 2021-06-30 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 7,368 | 93.00 | 685.2K | 7,368 | — | ↗ |
| 2021-06-30 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 7,368 | 93.00 | 685.2K | 7,368 | — | ↗ |
| 2021-06-30 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 7,368 | 93.00 | 685.2K | 7,368 | — | ↗ |
| 2021-06-30 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 7,368 | 93.00 | 685.2K | 7,368 | — | ↗ |
| 2021-06-30 | Bancroft Charles A | Director | A-Award | A | Stock Option (Right to Buy) | 7,368 | 93.00 | 685.2K | 7,368 | — | ↗ |
| 2021-06-30 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 7,368 | 93.00 | 685.2K | 7,368 | — | ↗ |
| 2021-06-29 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 7,079 | 89.87 | 636.2K | 12,791,909 | — | ↗ |
| 2021-06-28 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 10,459 | 91.87 | 960.8K | 12,784,830 | — | ↗ |
| 2021-06-21 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 475 | 82.22 | 39.1K | 66,658 | — | ↗ |
| 2021-06-15 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 1,147 | 84.75 | 97.2K | 64,968 | — | ↗ |
| 2021-06-15 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 3,619 | 0.00 | — | 171,609 | — | ↗ |
| 2021-06-11 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 111,850 | 73.51 | 8.22M | 111,850 | — | ↗ |
| 2021-06-11 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 2,900 | 0.00 | — | 66,115 | — | ↗ |
| 2021-06-11 | BORGESON JOHN A. | Officer | M-Exempt | A | Common Stock | 3,025 | 0.00 | — | 169,027 | — | ↗ |
| 2021-05-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 5,063 | 80.85 | 409.3K | 65,048 | — | ↗ |
| 2021-05-12 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 1,889 | 10.00 | 18.9K | 70,111 | — | ↗ |
| 2021-04-20 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 263,925 | — | ↗ |
| 2021-03-22 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 4,088 | 131.71 | 538.4K | 63,721 | — | ↗ |
| 2021-03-10 | BORGESON JOHN A. | Officer | S-Sale | D | Common Stock | 805 | 131.69 | 106.0K | 165,899 | — | ↗ |
| 2021-03-03 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,500 | 10.29 | 128.6K | 277,825 | — | ↗ |
| 2021-02-22 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 290,325 | — | ↗ |
| 2021-01-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 3,132 | 165.64 | 518.8K | 64,775 | — | ↗ |
| 2020-12-31 | PERLROTH VICTOR | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 10.29 | 77.2K | 324,225 | — | ↗ |
| 2020-12-21 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 408 | 144.59 | 59.0K | 46,563 | — | ↗ |
| 2020-11-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 981 | 138.56 | 135.9K | 47,648 | — | ↗ |
| 2020-11-20 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 116,158 | 108.00 | 12.55M | 1,143,396 | — | ↗ |
| 2020-10-27 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 10.29 | 77.2K | 345,625 | — | ↗ |
| 2020-10-23 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 10.29 | 77.2K | 353,125 | — | ↗ |
| 2020-10-20 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 360,625 | — | ↗ |
| 2020-10-13 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 5,000 | 75.00 | 375.0K | 42,843 | — | ↗ |
| 2020-10-09 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 15,000 | 0.00 | — | 48,984 | — | ↗ |
| 2020-09-25 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 557 | 58.09 | 32.4K | 1,027,238 | — | ↗ |
| 2020-09-24 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 2,081 | 52.11 | 108.5K | 1,024,049 | — | ↗ |
| 2020-09-23 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 74,381 | 52.44 | 3.90M | 11,246,368 | — | ↗ |
| 2020-09-22 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 779 | 49.72 | 38.7K | 1,011,373 | — | ↗ |
| 2020-09-21 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 372,575 | — | ↗ |
| 2020-09-08 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 185 | 45.88 | 8.5K | 10,982,957 | — | ↗ |
| 2020-09-04 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 9,101 | 47.50 | 432.3K | 10,982,772 | — | ↗ |
| 2020-09-03 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 2,359 | 46.97 | 110.8K | 10,793,451 | — | ↗ |
| 2020-08-21 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 3,386 | 47.74 | 161.7K | 980,106 | — | ↗ |
| 2020-08-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 4,359 | 47.53 | 207.2K | 33,984 | — | ↗ |
| 2020-08-20 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 283 | 46.30 | 13.1K | 972,555 | — | ↗ |
| 2020-08-19 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 3,585 | 46.99 | 168.4K | 10,606,135 | — | ↗ |
| 2020-07-20 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 386,475 | — | ↗ |
| 2020-07-02 | EHRLICH JASON | Officer | M-Exempt | A | Stock Option (Right to Buy) | 2,700 | 10.29 | 27.8K | 393,425 | — | ↗ |
| 2020-06-30 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 5,417 | 54.12 | 293.2K | 5,417 | — | ↗ |
| 2020-06-30 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 7,106 | 54.12 | 384.6K | 7,106 | — | ↗ |
| 2020-06-30 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 247,498 | 54.12 | 13.39M | 247,498 | — | ↗ |
| 2020-06-30 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 7,106 | 54.12 | 384.6K | 7,106 | — | ↗ |
| 2020-06-30 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 46,163 | 54.12 | 2.50M | 46,163 | — | ↗ |
| 2020-06-30 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 7,106 | 54.12 | 384.6K | 7,106 | — | ↗ |
| 2020-06-30 | Bancroft Charles A | Director | A-Award | A | Stock Option (Right to Buy) | 2,104 | 54.12 | 113.9K | 2,104 | — | ↗ |
| 2020-06-30 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 46,163 | 54.12 | 2.50M | 46,163 | — | ↗ |
| 2020-06-30 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 7,106 | 54.12 | 384.6K | 7,106 | — | ↗ |
| 2020-06-22 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 1,684 | 60.33 | 101.6K | 33,758 | — | ↗ |
| 2020-06-08 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 4,135 | 62.50 | 258.4K | 4,135 | — | ↗ |
| 2020-06-08 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 4,135 | 62.50 | 258.4K | 4,135 | — | ↗ |
| 2020-06-08 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 4,135 | 62.50 | 258.4K | 4,135 | — | ↗ |
| 2020-06-08 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 4,135 | 62.50 | 258.4K | 4,135 | — | ↗ |
| 2020-05-20 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,950 | 10.29 | 71.5K | 403,075 | — | ↗ |
| 2020-04-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 551 | 53.34 | 29.4K | 36,044 | — | ↗ |
| 2020-04-09 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 15,000 | 0.00 | — | 37,542 | — | ↗ |
| 2020-04-02 | Liang Hong | Officer | S-Sale | D | Common Stock | 4,000 | 42.34 | 169.4K | 130,166 | — | ↗ |
| 2020-04-02 | Bancroft Charles A | Director | — | D | Common Stock | 0 | 0.00 | — | 25,948 | — | ↗ |
| 2020-03-26 | Liang Hong | Officer | S-Sale | D | Common Stock | 2,545 | 47.28 | 120.3K | 135,621 | — | ↗ |
| 2020-03-20 | Levy Richard S | Director | P-Purchase | A | Common Stock | 250 | 43.37 | 10.8K | 250 | — | ↗ |
| 2020-03-20 | EHRLICH JASON | Officer | S-Sale | D | Common Stock | 1,458 | 43.59 | 63.5K | 27,801 | — | ↗ |
| 2020-03-19 | Liang Hong | Officer | S-Sale | D | Common Stock | 1,954 | 38.89 | 76.0K | 140,212 | — | ↗ |
| 2020-03-18 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,542 | 36.69 | 56.6K | 970,597 | — | ↗ |
| 2020-03-17 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 9,172 | 38.99 | 357.6K | 10,570,083 | — | ↗ |
| 2020-03-16 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 95,934 | 39.97 | 3.83M | 10,560,911 | — | ↗ |
| 2020-02-26 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 811 | 59.61 | 48.3K | 952,101 | — | ↗ |
| 2020-02-25 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 14,631 | 59.99 | 877.6K | 10,373,248 | — | ↗ |
| 2020-02-24 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,921 | 56.69 | 108.9K | 931,888 | — | ↗ |
| 2019-12-30 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 241,500 | 73.51 | 17.75M | 241,500 | — | ↗ |
| 2019-12-30 | Liang Hong | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 73.51 | 3.68M | 50,000 | — | ↗ |
| 2019-12-30 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 93,000 | 73.51 | 6.84M | 93,000 | — | ↗ |
| 2019-12-30 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 67,500 | 73.51 | 4.96M | 67,500 | — | ↗ |
| 2019-12-23 | EHRLICH JASON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,075 | 10.29 | 11.1K | 423,925 | — | ↗ |
| 2019-12-18 | EHRLICH JASON | Officer | M-Exempt | A | Common Stock | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2019-12-17 | Yang Taiyin | Director | A-Award | A | Stock Option (Right to Buy) | 8,855 | 71.20 | 630.5K | 8,855 | — | ↗ |
| 2019-12-06 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 1,743,993 | 46.00 | 80.22M | 10,118,929 | — | ↗ |
| 2019-12-02 | Liang Hong | Officer | M-Exempt | A | Common Stock | 12,916 | 1.06 | 13.7K | 142,166 | — | ↗ |
| 2019-09-19 | BAKER BROS. ADVISORS LP | Director / 10% Owner | X-InTheMoney | A | Common Stock | 1 | 0.01 | 0.01 | 8,374,936 | — | ↗ |
| 2019-07-16 | PERLROTH VICTOR | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 241,500 | 14.23 | 3.44M | 241,500 | — | ↗ |
| 2019-07-16 | Liang Hong | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 14.23 | 569.2K | 40,000 | — | ↗ |
| 2019-07-16 | EHRLICH JASON | Officer | A-Award | A | Stock Option (Right to Buy) | 93,000 | 14.23 | 1.32M | 93,000 | — | ↗ |
| 2019-07-16 | BORGESON JOHN A. | Officer | A-Award | A | Stock Option (Right to Buy) | 67,500 | 14.23 | 960.5K | 67,500 | — | ↗ |
| 2019-06-03 | PROFUSEK ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 24,747 | 10.13 | 250.7K | 24,747 | — | ↗ |
| 2019-06-03 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 24,747 | 10.13 | 250.7K | 24,747 | — | ↗ |
| 2019-06-03 | Dahiyat Bassil I | Director | A-Award | A | Stock Option (Right to Buy) | 24,747 | 10.13 | 250.7K | 24,747 | — | ↗ |
Executive team
Top executives
Shares Outstanding
52.93M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Victor Perlroth, M.D Chief Executive Officer | 792.5K | — | — | 923.0K | 772.8K | 10.9K | 2.50M | 36.93% | ↗ |
| 2 | 2025 | John A. Borgeson Executive Vice President, Chief | 553.0K | — | — | 678.7K | 373.3K | 10.9K | 1.62M | 42.00% | ↗ |
| 3 | 2024 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 756.6K | — | — | 679.6K | 541.0K | 10.8K | 1.99M | 34.18% | ↗ |
| 4 | 2024 | Victor Perlroth, M.D Chief Executive Officer | 756.6K | — | — | 679.6K | 541.0K | 10.8K | 1.99M | 34.18% | ↗ |
| 5 | 2024 | John A. Borgeson Executive Vice President, Chief | 525.0K | — | — | 559.9K | 259.9K | 10.8K | 1.36M | 41.30% | ↗ |
| 6 | 2024 | John A. Borgeson Executive Vice President, Chief Financial Officer and Secretary | 525.0K | — | — | 559.9K | 259.9K | 10.8K | 1.36M | 41.30% | ↗ |
| 7 | 2023 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 720.6K | — | — | 1.55M | 445.0K | 10.8K | 2.73M | 56.83% | ↗ |
| 8 | 2023 | John A. Borgeson Executive Vice President, Chief Financial Officer and Secretary | 497.1K | — | — | 959.2K | 212.6K | 10.8K | 1.68M | 57.11% | ↗ |
| 9 | 2023 | Jason Ehrlich, M.D., Ph.D. Former Chief Medical Officer and Chief Development Officer | 332.9K | — | — | 959.2K | — | 107.8K | 1.40M | 68.52% | ↗ |
| 10 | 2022 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 691.0K | — | — | 1.92M | 381.8K | 10.8K | 3.00M | 63.87% | ↗ |
| 11 | 2022 | Jason Ehrlich, M.D., Ph.D. Chief Medical Officer and Chief Development Officer | 496.5K | — | — | 840.0K | 189.9K | 99.4K | 1.63M | 51.67% | ↗ |
| 12 | 2022 | Jason Ehrlich, M.D., Ph.D. Former Chief Medical Officer and Chief Development Officer | 496.5K | — | — | 840.0K | 189.9K | 99.4K | 1.63M | 51.67% | ↗ |
| 13 | 2022 | John A. Borgeson Executive Vice President and Chief Financial Officer | 475.0K | — | — | 840.0K | 181.7K | 10.8K | 1.51M | 55.72% | ↗ |
| 14 | 2022 | John A. Borgeson Executive Vice President, Chief Financial Officer and Secretary | 475.0K | — | — | 840.0K | 181.7K | 10.8K | 1.51M | 55.72% | ↗ |
| 15 | 2021 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 655.0K | — | — | 112.19M | 512.8K | 10.3K | 113.37M | 98.96% | ↗ |
| 16 | 2021 | Jason Ehrlich, M.D., Ph.D. Chief Medical Officer and Chief Development Officer | 479.0K | — | 1.32M | 25.84M | 254.9K | 45.3K | 27.95M | 97.21% | ↗ |
| 17 | 2021 | John A. Borgeson Senior Vice President and Chief Financial Officer | 453.0K | — | 1.32M | 25.84M | 241.2K | 10.3K | 27.87M | 97.47% | ↗ |
| 18 | 2021 | John A. Borgeson Executive Vice President and Chief Financial Officer | 453.0K | — | 1.32M | 25.84M | 241.2K | 10.3K | 27.87M | 97.47% | ↗ |
| 19 | 2020 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 590.5K | — | — | 7.83M | 511.1K | 10.6K | 8.94M | 87.56% | ↗ |
| 20 | 2020 | Jason Ehrlich, M.D., Ph.D. Chief Medical Officer and Chief Development Officer | 462.2K | — | 783.4K | 1.46M | 277.3K | 72.7K | 3.06M | 73.42% | ↗ |
| 21 | 2020 | John A. Borgeson Senior Vice President and Chief Financial Officer | 425.5K | — | 783.4K | 1.46M | 255.4K | 11.8K | 2.94M | 76.41% | ↗ |
| 22 | 2019 | Victor Perlroth, M.D. Chief Executive Officer and Chairman of the Board | 525.7K | — | — | 16.71M | 392.6K | 9.5K | 17.64M | 94.74% | ↗ |
| 23 | 2019 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 525.7K | — | — | 16.71M | 392.6K | 9.5K | 17.64M | 94.74% | ↗ |
| 24 | 2019 | Jason Ehrlich, M.D., Ph.D. Chief Medical Officer and Chief Development Officer | 447.7K | — | 852.7K | 6.09M | 250.7K | 79.0K | 7.72M | 89.92% | ↗ |
| 25 | 2019 | John A. Borgeson Senior Vice President and Chief Financial Officer | 401.5K | — | 889.5K | 4.70M | 224.9K | 9.5K | 6.22M | 89.78% | ↗ |
| 26 | 2018 | Victor Perlroth, M.D Chief Executive Officer and Chairman of the Board | 427.5K | 300.0K | — | 5.17M | — | — | 5.90M | 87.66% | ↗ |
| 27 | 2018 | Victor Perlroth, M.D. Chief Executive Officer and Chairman of the Board | 427.5K | 300.0K | — | 5.17M | — | — | 5.90M | 87.66% | ↗ |
| 28 | 2018 | Victor Perlroth, M.D. Chief Executive Officer, President and Chairman of the Board | 427.5K | 300.0K | — | 5.17M | — | — | 5.90M | 87.66% | ↗ |
| 29 | 2018 | Jason Ehrlich, M.D., Ph.D. Chief Medical Officer and Chief Development Officer | 146.7K | 290.0K | 594.0K | 2.70M | — | 18.3K | 3.75M | 87.85% | ↗ |
| 30 | 2018 | John A. Borgeson Senior Vice President, Chief Financial Officer and Secretary | 327.2K | 180.0K | — | 1.61M | — | — | 2.11M | 75.99% | ↗ |
| 31 | 2018 | John A. Borgeson Senior Vice President and Chief Financial Officer | 327.2K | 180.0K | — | 1.61M | — | — | 2.11M | 75.99% | ↗ |
| 32 | 2017 | Victor Perlroth, M.D. Chief Executive Officer, President and Chairman of the Board | 387.0K | 294.8K | — | — | — | 141.3K | 823.1K | 0.00% | ↗ |
| 33 | 2017 | John A. Borgeson Senior Vice President, Chief Financial Officer and Secretary | 297.3K | 168.3K | — | — | — | — | 465.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President | 2M | — |
| John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary | 937.2K | male |
| Hong Liang | Senior Vice President of Development | 300.7K | — |
| Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing | — | — |
| Laurent Ducry | Senior Vice President of Biologics Development & Manufacturing | — | — |
| Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing | — | — |
| Almas Qudrat | Chief Quality Officer | — | female |
| Wayne To | Chief Technology Officer | — | male |
| Dolly S. Chang | Chief Scientific Officer | — | — |
| J. Pablo Velazquez-Martin | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KOD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
